



**HA NOI CPC1 PHARMACEUTICAL
JOINT STOCK COMPANY**

**SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness**

No. 44/2026/CV-CPC1HN

Ha Noi, April 20, 2026

Ref: Explanation regarding the profit after tax in the Income
Statement of quarter 1/2026 changing by 10% or more
compared to quarter 1/2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Pursuant to the Ministry of Finance's Circular 96/2020/TT-BTC, dated 16 November 2020, of guidance on information disclosure on the stock market.

Based on the Statement of Profit and Loss in the Financial Statements for the first quarter of 2026 and the first quarter of 2025, CPC1 Hanoi Pharmaceutical Joint Stock Company hereby provides an explanation for the fluctuation in profit after corporate income tax as follows:

Profit after CIT in Q1/2026 reached VND 55,408,421,991, an increase of VND 8,436,588,032 (equivalent to approximately 18%) compared to Q1/2025 (VND 46,971,833,959)

The main reasons for the fluctuation are as follows:

1. Increase in net revenue from sales and service provision

Net revenue in Q1/2026 reached VND 412,419,699,054, an increase of VND 82,901,835,364 (equivalent to 25.2%) compared to the same period last year.

This increase was mainly driven by the Company's efforts to enhance sales activities, expand distribution channels, and increase sales volume.

2. Increase in cost of goods sold and selling expenses

Cost of goods sold increased in line with revenue, thereby partially reducing gross profit.

Selling expenses increased due to the Company's expansion of sales support activities and market development initiatives.

3. Decrease in other expenses

Other expenses during the period decreased significantly compared to the same period last year, contributing positively to the increase in profit for the period.

Conclusion:

Due to the combined impact of the above factors, in which the increase in revenue and the decrease in other expenses were the key positive drivers, profit after CIT in Q1/2026 increased by VND 8,436,588,032 compared to Q1/2025.

The above constitutes the explanation of CPC1 Hanoi Pharmaceutical Joint Stock Company regarding the change in profit after CIT in the Q1/2026 Statement of Profit and Loss, which fluctuated by 10% or more compared to Q1/2025.

Sincerely,

Recipients:

- As addressed;
- Filing: Office Copy

CHAIRMAN OF THE BOARD OF DIRECTORS



Le Nam Thang